We combined LY2109761 with anti-PD-L1 and found that TGFβ inhibition increased the rate of tumor eradication from 33% with anti-PD-L1 alone to 77% with combination therapy and further reduced tumor growth relative to single agents or control alone (Fig. 1g, h). Here, TGFB1 is linked to neoplasm.